| # | Drug | Count |
|---|---|---|
| 0 | CAPECITABINE | 38 |
| 1 | LETROZOLE | 36 |
| 2 | BEVACIZUMAB | 34 |
| 3 | FLUOROURACIL | 32 |
| 4 | FLUOROURACIL CREAM, 0.5% | 32 |
| 5 | OXALIPLATIN | 32 |
| 6 | RIBOCICLIB | 31 |
| 7 | FULVESTRANT | 29 |
| 8 | OCTREOTIDE ACETATE | 27 |
| 9 | LETROZOLE TABLETS | 24 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ALDESLEUKIN | 2 | 0.0016 |
| 1 | GOSERELIN | 19 | 0.0014 |
| 2 | LEVOLEUCOVORIN INJECTION | 4 | 0.0013 |
| 3 | BUPRENORPHINE HCL | 1 | 0.0011 |
| 4 | LEVOLEUCOVORIN | 4 | 0.0010 |
| 5 | PANITUMUMAB | 16 | 0.0010 |
| 6 | IXABEPILONE | 1 | 0.0010 |
| 7 | RIBOCICLIB | 31 | 0.0009 |
| 8 | OCTREOTIDE ACETATE | 27 | 0.0009 |
| 9 | FULVESTRANT | 29 | 0.0009 |
| # | Drug class | Count |
|---|---|---|
| 0 | Aromatase Inhibitor [EPC] | 64 |
| 1 | Nucleoside Metabolic Inhibitor [EPC] | 62 |
| 2 | Platinum-based Drug [EPC] | 55 |
| 3 | Kinase Inhibitor [EPC] | 36 |
| 4 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 35 |
| 5 | Estrogen Receptor Antagonist [EPC] | 29 |
| 6 | Microtubule Inhibitor [EPC] | 29 |
| 7 | Epidermal Growth Factor Receptor Antagonist [EPC] | 23 |
| 8 | Corticosteroid [EPC] | 18 |
| 9 | Alkylating Drug [EPC] | 17 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Growth Factor [EPC] | 2 | 0.0016 |
| 1 | Estrogen Receptor Antagonist [EPC] | 29 | 0.0007 |
| 2 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 1 | 0.0007 |
| 3 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 4 | 0.0006 |
| 4 | Aromatase Inhibitor [EPC] | 64 | 0.0006 |
| 5 | Epidermal Growth Factor Receptor Antagonist [EPC] | 23 | 0.0005 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 62 | 0.0002 |
| 7 | Platinum-based Drug [EPC] | 55 | 0.0002 |
| 8 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 35 | 0.0002 |
| 9 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 4 | 0.0002 |